If at first you don't succeed at winning overtime pay, try again. At least that's the strategy of a former King Pharmaceuticals sales rep, who's suing the company for denying overtime for him and
In the ongoing fight about sales rep overtime pay, chalk up a win for management. As BNet Pharma reports, reps at King Pharmaceuticals' (NYSE: KG) Alpharma unit lost their bid to break out of the
Two big deals hit the papers today: King Pharmaceuticals is taking over Alpharma, and Johnson & Johnson has inked an agreement to buy Omrix. Together they amount to more than $2 billion in
King Pharmaceuticals, which has been courting Alpharma for months now, has finally gotten its wish. Alpharma rejected King's first offer of $1.4 billion back in September--although it was a 49
FDA staffers have expressed concern that Alpharma's powerful painkiller Embeda could be abused even though the company designed the drug not to be. Embeda contains morphine sulfate and Duramorph.
King Pharmaceuticals isn't backing off its hostile bid to acquire Alpharma. Today King announced that it is extending its tender offer for Class A Alpharma shares to November 21. The $37 per share
Methinks Alpharma did protest too much. The hard-to-get target of King Pharmaceuticals' takeover suit, Alpharma
After issuing its second bid, King warned Alpharma that it wouldn't take "no" for an answer.
King Pharmaceuticals can join the ranks of scorned
Following King Pharmaceuticals' beefed-up bid, Alpharma's board is urging shareholders not to